NDAINJECTIONINJECTABLEPriority Review
Approved
Dec 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
CYANOKIT (hydroxocobalamin) by Teva is poison. Approved for known, suspected cyanide poisoning. First approved in 2006.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYANOKIT (hydroxocobalamin) is an injectable antidote for known or suspected acute cyanide poisoning. It works by binding cyanide ions, forming cyanocobalamin which is then excreted in urine, reversing the inhibition of cellular respiration caused by cyanide's binding to cytochrome oxidase.
LOE Approaching
Product approaching loss of exclusivity with limited commercial team expansion likely; position focuses on maintaining market share in niche emergency medicine segment.
Mechanism of Action
poison. In the absence of rapid and adequate treatment, exposure to a high dose of cyanide can result in death within minutes due to the inhibition of cytochrome oxidase resulting in arrest of cellular respiration. Specifically, cyanide binds rapidly with cytochrome a3, a component of the…
Pharmacologic Class:
Antidote
Indications (2)
Worked on CYANOKIT at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.